142 related articles for article (PubMed ID: 2158152)
1. In vitro effect on Heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities.
Bara L; Mardiguian J; Samama M
Thromb Res; 1990 Feb; 57(4):585-92. PubMed ID: 2158152
[TBL] [Abstract][Full Text] [Related]
2. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
3. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
4. The haemorrhagic effect of low molecular weight heparins, dermatan sulphate and hirudin.
Matthíasson SE; Lindblad B; Stjernquist U; Bergqvist D
Haemostasis; 1995; 25(5):203-11. PubMed ID: 7489958
[TBL] [Abstract][Full Text] [Related]
5. Encapsulation of low molecular weight heparins: influence on the anti-Xa/anti-IIa ratio.
Javot L; Lecompte T; Rabiskova M; Maincent P
J Control Release; 2009 Oct; 139(1):8-14. PubMed ID: 19470393
[TBL] [Abstract][Full Text] [Related]
6. Effect of tissue factor pathway inhibitor (TFPI) in the HEPTEST assay and in an amidolytic anti factor Xa assay for LMW heparin.
Kristensen HI; Ostergaard PB; Nordfang O; Abildgaard U; Lindahl AK
Thromb Haemost; 1992 Sep; 68(3):310-4. PubMed ID: 1332210
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
8. Influence of different anticoagulant agents on fibrinopeptide a generation.
Tobu M; Iqbal O; Messmore HL; Ma Q; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2003 Oct; 9(4):273-92. PubMed ID: 14653437
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Bara L; Planes A; Samama MM
Br J Haematol; 1999 Feb; 104(2):230-40. PubMed ID: 10050702
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
11. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
[TBL] [Abstract][Full Text] [Related]
13. [Biological modifications induced by 3 low molecular weight heparins, PK 10169, Kabi 2165 and CY 216, compared to unfractionated heparin injected subcutaneously in healthy subjects in general surgery and in aged subjects in internal medicine].
Bara L; Combe-Tamzali S; Conard J; Horellou MH; Samama M
J Mal Vasc; 1987; 12 Suppl B():78-84. PubMed ID: 2834498
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
Danhof M; de Boer A; Magnani HN; Stiekema JC
Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
[TBL] [Abstract][Full Text] [Related]
15. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on a new one-stage clotting assay for heparin and its low molecular weight derivatives.
Harenberg J; Giese C; Knödler A; Zimmermann R
Haemostasis; 1989; 19(1):13-20. PubMed ID: 2537786
[TBL] [Abstract][Full Text] [Related]
17. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit.
Carrie D; Caranobe C; Boneu B
Br J Haematol; 1993 Apr; 83(4):622-6. PubMed ID: 8390849
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I.
Demir M; Iqbal O; Dietrich CP; Hoppensteadt DA; Ahmad S; Daud AN; Fareed J
Clin Appl Thromb Hemost; 2001 Jan; 7(1):44-52. PubMed ID: 11190904
[TBL] [Abstract][Full Text] [Related]
20. Laboratory analysis of blood samples from patients treated with tinzaparin.
Hoppensteadt DA; Willows L; Leitz H; Nicolaides A; Fareed J
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():49-55. PubMed ID: 15085466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
